Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:18 PM
Ignite Modification Date:
2026-03-26 @ 3:18 PM
NCT ID:
NCT07332767
Eligibility Criteria:
Inclusion Criteria:
* at least 18 years of age and
* Have a confirmed diagnosis of oHCM that is not solely explained by abnormal loading conditions such as significant hypertension or valvular disease
* Qualify for mavacamten therapy by exhibiting a peak Left Ventricular Outflow Tract (LVOT) gradient of ≥ 50mmHg at rest or with provocation, New York Heart Association (NYHA) functional class II or III symptoms, and a baseline Left Ventricular Ejection Fraction (LVEF) of ≥ 55%
Exclusion Criteria:
* HCM phenocopies such as cardiac amyloidosis or Fabry's disease
* Undergone a septal reduction therapy (myectomy or ablation) within the preceding 6 months
* Any contraindications to mavacamten (e.g., baseline LVEF \< 55%, pregnancy/breastfeeding)
* Inability to safely undergo a cardiac MRI, such as having non-compatible metal implants or severe claustrophobia
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
99 Years
Study:
NCT07332767
Study Brief:
Protocol Section:
NCT07332767